Main Article Content
Background: This study was designed to assess the efficacy of the combination of Desmopressin and Docetaxel for prostate cancer. Desmopressin has been demonstrated to inhibit tumor progression and metastasis in in vitro and in vivo models of breast cancer. Docetaxel, an anti-mitotic chemotherapeutic agent, is widely used for the treatment of castration resistant prostate cancer. However, it is associated with adverse effects and eventual drug resistance. This is the first report on the effect of combining Desmopressin and Docetaxel in prostate cancer, both in vitro and in vivo.
Methods: An established castrate resistant prostate cancer cell line DU145 was used. Cellular proliferation was determined using the MTS assay. The migratory inhibition potential of Desmopressin alone and in combination with Docetaxel was accessed using the wound healing assay. In vivo evaluation was performed on a prostate cancer xenograft model using athymic nude mouse. Treatment was administered bi- weekly and tumor volume were measured throughout the treatment period. Eventually, after a six-week treatment period, tumors were excised and measured.
Results: A combination therapy of 1 µM Desmopressin with 100nM Docetaxel resulted in dramatic inhibition of proliferation of DU145 cells 72 hours post treatment compared to either agent along (p < 0.05). Wound healing assay revealed inhibition of cellular migration as well (p<0.05). The use of a xenograft mouse model followed by treatment with 5 mg/kg Docetaxel intraperitoneally with concomitant 2 µg/ml/kg Desmopressin administered intravenously 30 minutes before administering chemotherapy and 24 hours after, resulted in a significant decrease in tumor volume (P<0.05), while not impacting body weight.
Conclusions: Desmopressin significantly enhanced the anti-proliferative and inhibiting the migratory potential of Docetaxel. Combination treatment had no additional effect on mice weight or mortality. These studies could enhance the efficacy of Docetaxel- based chemotherapy treatment for castrate resistant prostate cancer.
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aÂ Creative Commons Attribution LicenseÂ that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).
 IF Tannock, R de Wit, WR Berry et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502-1512.
 DP Petrylak, CM Tangen, MH Hussain et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513-1520.
 J Kroon, S Kooijman, NJ Cho et al (2016) Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. Trend in pharmacological science. 37: 451-462.
 H Sasaki, LH Klotz, LM Sugar et al (2015) A combination of Desmopressin and Docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. Biochem Biophys Res Commun. 464: 848-854.
 NA Vanier, J Alexandra, AJ Colquhoun et al (2015) Capsaicin: A novel radio-sensitizing agent for prostate cancer. The Prostate. 75:113–125.
 CC Liang, AY Park, JL Guan (2007) In vitro scrach assay: a convenient and inexpensive method of analysis of cell migration in vitro. Nat Protocol 2. 329-333.
 R Fridman, G Benton, I Aranoutova et al (2012) Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection. Nature protocols 2. 1138.
 NB Iannucci, GV Ripoll, J Garona et al (2011) Antiproliferative effect of 1-deamino-8-darginine vasopressin analogs on human breast cancer cells. Future Med Chem 3. 1987–1993.
 KR Stone, DD Mickey, H Wunderli et al (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer. 21: 274–281.
 LE Pascal LE, RZ Vêncio, RL Vessella et al (2011) Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics. 23: 46.
 JE Kaufman, UM Vischer (2003) Cellular mechanisms of the hemostatic effects of Desmopressin (DDAVP). J Thromb Haemost. 1: 682-689.
 GP Luo, B Ni, X Yang et al (2012) Von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 128: 158-169.
 DF Alonso, G Skilton, EF Farías et al (1999) Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat. 57: 271-275.
 J Garona, DF Alonso (2014) Reciprocal interactions between tumor and endothelial cells: effects of selective vasopressin V2 receptor peptide agonists. Cancer Cell & Microenvironment. 1: 23.
 M Zhong, ML Boseman, AC Millena et al (2010) Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res. 8: 1164-1172.
 Gene expression omnibus profile database on the National center for biotechnology information. http://www.ncbi.nlm.nih.gov/geo/. Accessed 1 September 2016.
 S Giron, AM Tejera, GV Ripoll et al (2002) Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surgical Oncol. 81: 38–44.